

Amendments to the Claims

This listing of claims will replace all prior versions, and listing of claims in the application.

Applicants cancel claims 2-6 and 10-13. Applicants amend claims 7-9 and 14, 16, and 17.

1. (Original) An anti-myostatin monoclonal antibody comprising two polypeptides with the sequences shown in the group consisting of:

- (i) SEQ ID NOS: 3 and 12,
- (ii) SEQ ID Nos: 4 and 13,
- (iii) SEQ ID Nos: 3 and 14,
- (iv) SEQ ID Nos: 5 and 12,
- (v) SEQ ID Nos: 6 and 15,
- (vi) SEQ ID Nos: 7 and 17,
- (vii) SEQ ID Nos: 8 and 12,
- (viii) SEQ ID Nos: 9 and 16,
- (ix) SEQ ID Nos: 10 and 12, and
- (x) SEQ ID Nos: 11 and 12.

2.-6. (Canceled)

7. (Currently amended) The monoclonal antibody of claim 1, any of claims 1-6 wherein the monoclonal antibody is a full-length antibody, a substantially intact antibody, a chimeric antibody, a Fab fragment, a F(ab')₂ fragment or a single chain Fv fragment.

8. (Currently amended) The monoclonal antibody of claim 1, any of claims 1-7 wherein the monoclonal antibody is a humanized antibody.

9. (Currently amended) The monoclonal antibody of claim 1, any of Claims 1-6 wherein the constant region present in the antibody originates from the genome of an animal selected from the group consisting of domestic animals, sports animals and food-source animals.

10.-13. (Canceled)

14. (Currently amended) A pharmaceutical composition comprising the antibody of claim 1, any one of claims 1-9, 11 and 13.
15. (Original) The pharmaceutical composition of claim 14 further comprising a pharmaceutically acceptable carrier.
16. (Currently amended) A method of increasing muscle mass comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 14, any one of claims 14-15.
17. (Currently amended) A method of treating or preventing frailty, cachexia, muscle wasting, muscle weakness, myopathy, muscular dystrophy, osteoporosis, COPD, renal failure or disease, liver failure or disease, cardiac failure, type II diabetes or metabolic syndrome by administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 14, any one of claims 14-15.